Introduction {#sec1-1}
============

Retinoblastoma is the most frequent childhood intraocular tumor with a global incidence of 1:20,000 births.\[[@ref1]\] Global incidence data for retinoblastoma show an approximate 50-fold variation, which is highly atypical for a pediatric tumor. Incidence of Retinoblastoma on a global scale is 11/ million children in 5 years and younger age group. In India, incidence rate stands at 0.6 cases per 100,000 children. Nagpur Cancer Registry reports a prevalence of 0.1/100,000 population. Management of retinoblastoma has changed during years with a survival rate of \>95% in developed countries.\[[@ref2][@ref3]\] However, in developing countries, cure rates of \<50% are observed, primarily because of advanced disease at the time of diagnosis.\[[@ref4][@ref5][@ref6]\] Data detailing the clinical presentation and treatment outcomes of retinoblastoma, especially in Indian settings, are scarce, and hence, this study was undertaken to assess the clinical profile of patients with retinoblastoma.

Subjects and Methods {#sec1-2}
====================

A retrospective cohort study was conducted by reviewing clinical records of all retinoblastoma patients (*n* = 141) registered from 1983 to 2013 at Government Medical College and Hospital, Nagpur, India. The Institutional Ethics Committee approval was obtained. The diagnosis of retinoblastoma was based on history and physical examination with complete ocular examination. Demographics, clinical presentation, follow-up examinations, and outcome of the patients were noted.

Results {#sec1-3}
=======

One hundred and sixty-two eyes in 141 patients were diagnosed with retinoblastoma. Numbers of patients recorded during the first decade (1982--1993), second decade (1994--2003), and third decade (2004--2013) were 72, 44, and 25, respectively. The mean follow-up of all patients was 112 days (0--791).

Clinical profile of the patients has been described in [Table 1](#T1){ref-type="table"}. [Figure 1](#F1){ref-type="fig"} shows appreciable change in trends during the management of retinoblastoma patient over three decades.

###### 

Demographics and clinical profile (*n*=141 patients)

  Variables                                                                        Frequency, *n* (%)
  -------------------------------------------------------------------------------- --------------------
  **Age at diagnosis (years)**                                                     
   \<1                                                                             2 (1.5)
   1-3                                                                             81 (57.5)
   \>3                                                                             58 (41.1)
  **Gender distribution**                                                          
   Males                                                                           81 (57.5)
   Females                                                                         60 (42.5)
  **Laterality**                                                                   
   Unilateral                                                                      114 (80.9)
   Bilateral                                                                       24 (17)
   Trilateral                                                                      2 (1.4)
   Quadrilateral                                                                   1 (0.7)
  **Presenting signs and symptoms**                                                
   White eye                                                                       36 (25.5)
   Orbital swelling/proptosis                                                      81 (57.5)
   Painful eye                                                                     10 (7.1)
   Loss of vision                                                                  12 (8.5)
   Squint                                                                          2 (1.4)
  **Complications**                                                                
   Calcification                                                                   45 (31.9)
   Retinal hemorrhage                                                              15 (10.6)
   Vitreous seeding                                                                1 (0.7)
   Retinal detachment                                                              7 (5)
   Other\*                                                                         73 (51.8)
  **Presence of local invasion**                                                   
   Optic nerve and soft-tissue involvement                                         36 (25.5)
   Multiple site involvement                                                       12 (8.5)
   Bone erosion                                                                    4 (2.8)
   No local invasion                                                               52 (36.9)
  **Distant metastasis**                                                           
   Extracranial                                                                    26 (18.4)
   Intracranial                                                                    16 (11.3)
   Both intracranial and extracranial                                              2 (1.4)
  **Grouping as per Reese-Ellsworth classification (n=139)**                       
   1                                                                               4 (2.9)
   2                                                                               8 (5.8)
   3                                                                               23 (16.6)
   4                                                                               14 (10.1)
   5                                                                               90 (64.8)
  **Grouping as per the International Classification of Retinoblastoma (n=139)**   
   A                                                                               3 (2.2)
   B                                                                               13 (9.4)
   C                                                                               14 (10.1)
   D                                                                               24 (17.3)
   E                                                                               85 (61.2)
  **Mode of treatment^\#^**                                                        
   **Surgical**                                                                    
    Enucleation                                                                    65 (46.1)
    Exenteration                                                                   9 (6.4)
    Craniotomy and excision                                                        1 (0.7)
   Nonsurgical                                                                     66 (46.8)
   Adjuvant/neoadjuvant chemotherapy\#                                             46 (32.6)
  **Radiotherapy**                                                                 
   Radical intent                                                                  29 (20.6)
   Adjuvant (postoperative)                                                        46 (32.6)
   Palliation (due to metastasis)                                                  28 (19.9)
  Outcome after therapy                                                            
   Recurrence                                                                      54 (38.3)
   Disease free at the last follow-up                                              43 (30.5)
   Unknown (lost for follow-up)                                                    44 (31.2)
  Outcome on long-term follow-up                                                   
   Mortality                                                                       112 (79.43)
   Alive without disease                                                           13 (9.21)
   Lost for follow-up                                                              16 (11.3)

\*Perforation of globe, staphyloma, raised ICT, raised IOT, fungating growth, lymphadenopathy, ^\#^All patients, except one, received VAC regimen of chemotherapy. VAC=Vincristine, adriamycin, cyclophosphamide, ICT=Intra-cranial tension, IOT=Intra-ocular tension

![Trends in the management of retinoblastoma over the years. Data expressed in percentages. Over the years, an increase in chemotherapeutic approach as treatment of choice, slight decrease in surgical approach and sharp decrease in radiotherapy approach have been observed in the management of retinoblastoma](SAJC-8-195-g001){#F1}

Discussion {#sec1-4}
==========

Retinoblastoma is a rare disease of early childhood. Due to extremely low incidence, the features of retinoblastoma patients are not routinely assessed. In developing countries such as India, it is important to identify the clinical features on presentation and complications of these patients. Data from developed countries and urban treatment centers in India show leukocoria (white eye) as a leading presenting symptom (early diagnosis) along with excellent survival status with the highest level of quality of life. The present study shows data in sync with data from developing countries with respect to late diagnosis, advanced stage at presentation & poor outcomes/loss of follow up.\[[@ref7][@ref8][@ref9][@ref10][@ref11]\] Presentation for late cases varies from proptosis to fungating mass with secondaries.\[[@ref12]\] Presentation of proptosis in majority of cases can be attributed to the delay in seeking consultation by the patient.\[[@ref13]\] Extraocular retinoblastoma is very rare in developed countries (2%--5%).\[[@ref14]\] In developing nations, extraocular disease contributes to half of all retinoblastoma cases presenting to a tertiary care referral center, which is in accordance with the findings of this study.\[[@ref15][@ref16]\]

Reese--Ellsworth grading, formulated in 1960, has been widely used to predict the outcome of retinoblastoma treated with external beam radiotherapy (EBRT); however, as chemotherapy gradually replaced radiotherapy, new staging system was developed to predict the outcome for eyes treated with chemotherapy and focal treatments, which were international intraocular retinoblastoma. Majority of cases presented in an advanced stage. These findings were in accordance with data from other developing nations.\[[@ref7][@ref10][@ref11]\]

Surgical management and EBRT are considered standard treatment protocol for eyes with advanced stage. Resource deficiency, unavailability, and cost of drugs till 1990s precluded the use of chemotherapy in majority of patients in this study. However, with changing guidelines and availability of standard drugs, number of patients receiving chemotherapy increased appreciably, coinciding with decrease in patient being treated with surgery and EBRT, which has been observed in [Figure 1](#F1){ref-type="fig"}.

EBRT was the only alternative to enucleation until the mid-1990s and is still an option to treat large tumors.\[[@ref17]\] Scarce supply of ketamine till 1990s as anesthetic agent used for immobilizing pediatric patients before radiation therapy session prompted use of hypofractionated RT, which enabled treatment to be completed in less duration. Dose prescribed in patients treated with radical intent was 36 gy/9 fractions in 2--3 weeks, which was equivalent to conventional 50 Gy/5 times per week fractionation.\[[@ref18]\]

Treatment abandonment as well as loss to follow-up has also been reported from other developing countries,\[[@ref10][@ref19][@ref20]\] which could be attributed to no response/progressive disease in an advanced stage, inability to accept enucleation as form of treatment, inability to cope up with frequency of follow-up, illiteracy, poverty, and negligence.

To unearth grim situation, specifically in India, as per one retinoblastoma world statistical analysis, China recorded 1095 retinoblastoma patients in 2013 in 28 established Retinoblastoma Treatment Centers (RTB), while Pakistan showed 312 patients in 6 RTBs, while in India, 1730 patients took treatment in 11 RTBs. Various approaches for improvement in the management of retinoblastoma in developing countries\[[@ref19]\] have been summarized in [Figure 2](#F2){ref-type="fig"}.

![Recommendations for improving management of retinoblastoma in developing countries](SAJC-8-195-g002){#F2}

Conclusions {#sec1-5}
===========

Data from this study show late diagnosis, leading to poor outcome for patients with advanced retinoblastoma, which is in accordance with data from other developing countries. Even though management of patients changed in accordance with changing standard of care over the decade, mortality remained high. Inequality in patient access to health care is the reality in India. This study underlines this well-known fact and brings forth strategies which can lead to improvement of this scenario.
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